What is Tosk?
Tosk Inc. is a biopharmaceutical company dedicated to improving cancer treatment outcomes through the development of novel drugs. The company's focus lies in creating innovative therapies that enhance the safety and efficacy of existing treatments while simultaneously targeting cancer gene activity. Utilizing proprietary methods, Tosk develops small, cost-effective molecules designed to mitigate the adverse side effects commonly associated with current cancer therapies. Their pioneering technology also aims to discover drugs for previously undruggable indications, with an initial focus on the mutant KRAS gene, a key factor in a substantial percentage of cancer diagnoses. Tosk's overarching mission is to elevate the quality of life for cancer patients by addressing treatment-related side effects and directly targeting cancer-driving genes, positioning itself within the global oncology market.
How much funding has Tosk raised?
Tosk has raised a total of $6.2M across 2 funding rounds:
Private Equity
$5.4M
Private Equity
$766K
Private Equity (2011): $5.4M, investors not publicly disclosed
Private Equity (2016): $766K, investors not publicly disclosed
What's next for Tosk?
The substantial enterprise-level funding and recent strategic investment signal a critical growth phase for Tosk. This capital infusion is expected to accelerate the advancement of its drug pipeline, particularly its efforts targeting the mutant KRAS gene and other undruggable indications. The company is poised to further its research and development, potentially moving towards clinical trials and eventual commercialization. Tosk's strategic focus on enhancing treatment safety and efficacy, alongside its innovative approach to drug discovery, positions it for significant impact in the biopharmaceutical sector, aiming to capture a considerable share of the global cancer treatment market.
See full Tosk company page
